Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
:AVDL
AVDL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.38 - $17.30
Previous CloseN/A
Volume358.54K
Average Volume (3M)1.03M
Market Cap
$1.08B
Enterprise Value$728.31M
Total Cash (Recent Filing)$66.48M
Total Debt (Recent Filing)$2.90M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 05, 2025EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding96,892,980
10 Day Avg. Volume799,910
30 Day Avg. Volume1,031,803
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue3.75
Enterprise Value/Gross Profit4.16
Enterprise Value/Ebitda-50.39
Forecast
1Y Price Target
$21.00Price Target Upside88.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Market ExpansionAvadel Pharmaceuticals announced an increase in expected patient numbers and revenue for their product Lumryz, signaling strong future growth.
Patent ProtectionLUMRYZ is likely to remain patent-protected into at least the late 2030s, with multiple patents providing protection into 2042.
Regulatory ApprovalAvadel Pharmaceuticals announced that LUMRYZ has received Orphan Drug Designation from the FDA for the treatment of idiopathic hypersomnia.
Bears Say
Investor SentimentAvadel's current stock price reflects excessively conservative investor sentiment, underrating the market opportunity for LUMRYZ in narcolepsy and its potential in idiopathic hypersomnia.
Patent ChallengesThe company is actively challenging patent issues, which may protect its market position and lead to further competitive advantages.
Avadel Pharmaceuticals News
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $6.38 and its highest was $17.30 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $1.08B.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.069.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Undervalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is 0.08.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 96,892,980 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 9.606%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
Avadel Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (88.34% Upside)
$21.00 (88.34% Upside)
Blogger Sentiment
Neutral
AVDL Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 13.4%
Last 30 Days ▲ 13.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.25%
12-Months-Change
Fundamentals
Return on Equity
-34.65%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals (AVDL) is a publicly traded biopharmaceutical company focused on developing and commercializing innovative medications for conditions with significant unmet medical needs. The company primarily concentrates on the therapeutic areas of sleep medicine, offering solutions that aim to improve the quality of life for patients. Avadel is known for its flagship product, LUMRYZ™, which is designed to address excessive daytime sleepiness in patients with narcolepsy.
AVDL Company Deck
AVDL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment driven by strong growth in LUMRYZ adoption and favorable legal outcomes, alongside raised financial guidance. However, some caution remains due to typical Q1 seasonality effects and potential impacts from ongoing legal and tariff challenges.View all AVDL earnings summariesAVDL Stock 12 Month Forecast
Average Price Target
$21.00
▲(88.34% Upside)
Technical Analysis
Emergent Biosolutions
―
Esperion
―
Collegium Pharmaceutical
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
0.93% Insiders
10.69% Mutual Funds
2.59% Other Institutional Investors
76.13% Public Companies and
Individual Investors